CONMED Corp.

NYS: CNMD

GO
/marketstate/country/us

Market open

 --Real time quotes

Apr 9, 2020, 10:56 a.m.

/zigman2/quotes/208421017/composite

$

72.82

Change

+6.30 +9.47%

Volume

Volume 151,722

Real time quotes

/zigman2/quotes/208421017/composite

Previous close

$ 66.52

$ 72.82

Change

+6.30 +9.47%

Day low

Day high

$67.72

$74.67

Open

52 week low

52 week high

$37.66

$116.81

Open

Company Description

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and ...

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.

Valuation

P/E Current

68.55

P/E Ratio (with extraordinary items)

70.90

P/E Ratio (without extraordinary items)

115.25

Price to Sales Ratio

3.48

Price to Book Ratio

4.47

Price to Cash Flow Ratio

34.67

Enterprise Value to EBITDA

24.74

Enterprise Value to Sales

3.66

Total Debt to Enterprise Value

0.20

Efficiency

Revenue/Employee

287,008.00

Income Per Employee

8,673.00

Receivables Turnover

5.11

Total Asset Turnover

0.60

Liquidity

Current Ratio

2.11

Quick Ratio

1.24

Cash Ratio

0.14

Profitability

Gross Margin

51.52

Operating Margin

9.40

Pretax Margin

3.30

Net Margin

3.02

Return on Assets

1.82

Return on Equity

4.17

Return on Total Capital

6.79

Return on Invested Capital

2.22

Capital Structure

Total Debt to Total Equity

111.64

Total Debt to Total Capital

52.75

Total Debt to Total Assets

44.68

Long-Term Debt to Equity

108.70

Long-Term Debt to Total Capital

51.36

Officers and Executives

Name Age Officer Since Title
Mr. Mark E. Tryniski 58 2007 Lead Independent Director
Mr. Curt R. Hartman 55 2014 Director
Mr. Todd W. Garner 50 2018 Chief Financial Officer & Executive Vice President
Mr. Ronald Bellamy - 1994 Administration Manager
Mr. Pete K. Shagory - 2015 Executive VP-Strategy & Corporate Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/31/2020 Daniel S. Jonas
EVP Legal Affairs,Gen. Counsel
224   Award at $54.41 per share. 12,187
03/31/2020 Heather L. Cohen
EVP CORP HR
224   Award at $54.41 per share. 12,187
03/31/2020 Todd W. Garner
Executive Vice President & CFO
224   Award at $54.41 per share. 12,187
03/31/2020 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
112   Award at $54.41 per share. 6,093
03/31/2020 Stanley W. Peters
VP GM Advanced Surgery
224   Award at $54.41 per share. 12,187
03/02/2020 John L. Workman
Director
2,000   Acquisition at $94.63 per share. 189,260
02/28/2020 Curt R. Hartman
President & CEO; Director
2,250   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Terence M. Bergé
VP-Corporate Controller
250   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Daniel S. Jonas
EVP Legal Affairs,Gen. Counsel
350   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Heather L. Cohen
EVP CORP HR
300   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Patrick Joseph Beyer
President - International
725   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 John E. Kennedy
VP GM CET
1,250   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 John E. Kennedy
VP GM CET
325   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Johonna Pelletier
Treasurer and VP, Tax
125   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Todd W. Garner
Executive Vice President & CFO
1,600   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Nathan Folkert
VP GM Orthopedics
400   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Nathan Folkert
VP GM Orthopedics
500   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
400   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
375   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Pete K. Shagory
EVP, STRAT & CORP DEVT
300   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Stanley W. Peters
VP GM Advanced Surgery
425   Derivative/Non-derivative trans. at $0 per share. 0
02/28/2020 Terence M. Bergé
VP-Corporate Controller
123   Derivative/Non-derivative trans. at $94.64 per share. 11,640
02/28/2020 Daniel S. Jonas
EVP Legal Affairs,Gen. Counsel
175   Derivative/Non-derivative trans. at $94.64 per share. 16,562
02/28/2020 Heather L. Cohen
EVP CORP HR
102   Derivative/Non-derivative trans. at $94.64 per share. 9,653
02/28/2020 Patrick Joseph Beyer
President - International
341   Derivative/Non-derivative trans. at $94.64 per share. 32,272
02/28/2020 John E. Kennedy
VP GM CET
367   Derivative/Non-derivative trans. at $94.64 per share. 34,732
02/28/2020 John E. Kennedy
VP GM CET
96   Derivative/Non-derivative trans. at $94.64 per share. 9,085
02/28/2020 Johonna Pelletier
Treasurer and VP, Tax
62   Derivative/Non-derivative trans. at $94.64 per share. 5,867
02/28/2020 Todd W. Garner
Executive Vice President & CFO
784   Derivative/Non-derivative trans. at $94.64 per share. 74,197
02/28/2020 Nathan Folkert
VP GM Orthopedics
98   Derivative/Non-derivative trans. at $94.64 per share. 9,274
02/28/2020 Nathan Folkert
VP GM Orthopedics
122   Derivative/Non-derivative trans. at $94.64 per share. 11,546
02/28/2020 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
118   Derivative/Non-derivative trans. at $94.64 per share. 11,167
02/28/2020 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
111   Derivative/Non-derivative trans. at $94.64 per share. 10,505
02/28/2020 Pete K. Shagory
EVP, STRAT & CORP DEVT
88   Derivative/Non-derivative trans. at $94.64 per share. 8,328
02/28/2020 Stanley W. Peters
VP GM Advanced Surgery
124   Derivative/Non-derivative trans. at $94.64 per share. 11,735
02/04/2020 Stanley W. Peters
VP GM Advanced Surgery
187   Disposition at $104.18 per share. 19,481
01/31/2020 Curt R. Hartman
President & CEO; Director
48,903   Derivative/Non-derivative trans. at $101.68 per share. 4,972,457
01/31/2020 Curt R. Hartman
President & CEO; Director
104,000   Derivative/Non-derivative trans. at $0 per share. 0
01/02/2020 Todd W. Garner
Executive Vice President & CFO
1,040   Derivative/Non-derivative trans. at $111.23 per share. 115,679
01/02/2020 Todd W. Garner
Executive Vice President & CFO
2,000   Derivative/Non-derivative trans. at $0 per share. 0
12/31/2019 Heather L. Cohen
EVP CORP HR
48   5,367
12/31/2019 Wilfredo Ruiz-Caban
EVP QA, RA and Operations
16   Award at $106.24 per share. 1,699
12/31/2019 Stanley W. Peters
VP GM Advanced Surgery
44   Award at $106.24 per share. 4,674
12/13/2019 Pete K. Shagory
EVP, STRAT & CORP DEVT
1,500   Disposition at $111.02 per share. 166,530
12/13/2019 Pete K. Shagory
EVP, STRAT & CORP DEVT
1,500   Derivative/Non-derivative trans. at $41.93 per share. 62,895
12/09/2019 John E. Kennedy
VP GM CET
5,965   Disposition at $112.42 per share. 670,585
12/05/2019 John E. Kennedy
VP GM CET
13,555   Derivative/Non-derivative trans. at $113.91 per share. 1,544,050
12/05/2019 John E. Kennedy
VP GM CET
19,520   Derivative/Non-derivative trans. at $51.3 per share. 1,001,376
/news/latest/company/us/cnmd

MarketWatch News on CNMD

  1. Conmed now sees Q1 EPS growth in mid-single digits vs. prior high-single digit to low double-digit range

    7:09 a.m. March 10, 2020

    - Ciara Linnane

  2. Conmed issues Q1 revenue warning to reflect impact of coronavirus

    7:06 a.m. March 10, 2020

    - Ciara Linnane

  3. Conmed now sees Q1 revenue up 2% to 4%, vs. prior guidance 5% to 6%

    7:07 a.m. March 10, 2020

    - Ciara Linnane

  4. Conmed downgraded to hold from buy at Needham

    10:15 a.m. Nov. 26, 2019

    - Tonya Garcia

  5. Conmed price target raise to $130 from $118 at Stifel

    8:32 a.m. Nov. 25, 2019

    - Tonya Garcia

  6. Conmed started at overweight with $136 stock price target at J.P. Morgan

    8:54 a.m. Nov. 12, 2019

    - Tomi Kilgore

  7. Conmed started at buy with $95 stock price target at Stifel Nicolaus

    8:42 a.m. April 18, 2019

    - Tomi Kilgore

  8. Conmed reiterated as buy at Needham

    8:55 a.m. Dec. 14, 2018

    - Ciara Linnane

  9. Legion Partners Takes a 5.2% Position in Primo Water

    8:58 p.m. June 8, 2018

    - Barron's Online

  10. Cevian Capital Kicks Autoliv’s Tires

    8:00 p.m. March 16, 2018

    - Barron's Online

  11. Activist Wildcat Circles Sorrento Therapeutics

    11:48 p.m. May 13, 2016

    - Barron's Online

  12. 13D Filings

    3:40 a.m. Feb. 15, 2014

    - Barron's Online

  13. 13D Filings

    5:15 a.m. Dec. 21, 2013

    - Barron's Online

  14. Correct Care to purchase Conmed for $59M

    9:24 a.m. July 16, 2012

    - MarketWatch.com

  15. Monday's biggest gaining and declining stocks

    6:23 p.m. Jan. 5, 2009

    - MarketWatch

  16. Three ways to play defense in October

    12:01 a.m. Oct. 1, 2008

    - Michael Ashbaugh

  17. U.S. markets lift from multi-year lows

    10:04 a.m. Sept. 25, 2008

    - Michael Ashbaugh

  18. Staking out critical support

    10:33 a.m. Sept. 22, 2008

    - Michael Ashbaugh

  19. Loading more headlines...
/news/nonmarketwatch/company/us/cnmd

Other News on CNMD

  1. Needham Reaffirms Their Hold Rating on Conmed (CNMD)

    8:28 a.m. March 20, 2020

    - SmarterAnalyst

  2. Here's Why You Should Hold on to CONMED (CNMD) Stock Now

    9:30 a.m. March 12, 2020

    - Zacks.com

  3. Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show

    9:20 a.m. March 12, 2020

    - Zacks.com

  4. Needham Sticks to Its Hold Rating for Conmed (CNMD)

    8:48 a.m. March 10, 2020

    - SmarterAnalyst

  5. Conmed cuts Q1 outlook due to COVID-19

    7:29 a.m. March 10, 2020

    - Seeking Alpha

  6. Why Is Conmed (CNMD) Down 6.5% Since Last Earnings Report?

    11:31 a.m. Feb. 28, 2020

    - Zacks.com

  7. XRAY vs. CNMD: Which Stock Is the Better Value Option?

    11:40 a.m. Feb. 25, 2020

    - Zacks.com

  8. 10-K: CONMED CORP

    1:33 p.m. Feb. 24, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  9. The VP GM Advanced Surgery of Conmed (CNMD) is Selling Shares

    8:49 p.m. Feb. 6, 2020

    - SmarterAnalyst

  10. XRAY or CNMD: Which Is the Better Value Stock Right Now?

    11:40 a.m. Feb. 5, 2020

    - Zacks.com

  11. CONMED (CNMD) Earnings and Revenues Beat Estimates in Q4

    9:37 a.m. Jan. 31, 2020

    - Zacks.com

  12. Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates

    5:45 p.m. Jan. 29, 2020

    - Zacks.com

  13. Notable earnings after Wednesday's close

    5:35 p.m. Jan. 28, 2020

    - Seeking Alpha

  14. Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

    12:31 p.m. Jan. 22, 2020

    - Zacks.com

  15. Loading more headlines...

At a Glance

CONMED Corp.

525 French Road

Utica, New York 13502

Phone

1 3157978375

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$947.13M

Net Income

$28.62M

2019 Sales Growth

10.3%

Employees

3,300

/news/pressrelease/company/us/cnmd

Press Releases on CNMD

  1. Enteroscope Market Size & Share | Industry Analysis Report, 2020-2027

    3:12 a.m. April 7, 2020

    - Global QYResearch

  2. Loading more headlines...
Link to MarketWatch's Slice.